Ionis Pharmaceuticals, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
IONS Company Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
IONS Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view IONS Smart Score
Score Breakdown
IONS Company Description
Show More
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of IONS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by IONS's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on IONS's company Twitter account
WallStreetBets
Number of mentions of IONS in WallStreetBets Daily Discussion
IONS News
Recent insights relating to IONS
CNBC Recommendations
Recent picks made for IONS stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in IONS
Corporate Flights
Flights by private jets registered to IONS
Our Analysis